This week in drug discovery (27 – 30 June)

News round-up by DDW’s Reece Armstrong for 27 – 30 June.

Assays for monkeypox, Covid-19 boosters and approvals for oncology drugs are some of the themes of this week’s news round-up.

GSK & Sanofi first to report positive data for Omicron booster  

GSK and Sanofi have reported positive efficacy data from a co-developed vaccine targeting the Omicron variant of Covid-19. The report makes GSK and Sanofi the first companies to have a vaccine candidate for the Omicron variant which has demonstrated efficacy.

UK’s NICE recommends Eli Lilly’s breast cancer drug  

Early breast cancer patients in England will be able to access a new form of treatment following the recommendation for Eli Lilly’s abemaciclib by the National Institute of Health and Care Excellence (NICE).

US launches trial for potential universal flu vaccine

The National Institutes of Health (NIH) has launched a Phase I clinical trial for a potential universal flu vaccine.

Project granted £4.25m to advance research in motor neurone disease 

Six UK universities have collectively received £4.25 million as part of a collaborative project aimed at finding new treatments for motor neurone disease (MND).

Novacyt launches monkeypox assay in response to outbreak  

Clinical diagnostics company Novacyt has launched a polymerase chain reaction (PCR) monkeypox assay in response to the recent outbreak of the virus non-endemic countries.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free